FYARRO (SIROLIMUS)
FYARRO (SIROLIMUS) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: FYARRO; Generic name: SIROLIMUS; Drug class: mTOR Inhibitor Immunosuppressant [EPC].
| Brand name | FYARRO |
|---|---|
| Generic name | SIROLIMUS |
| Drug class | mTOR Inhibitor Immunosuppressant [EPC] |
| Manufacturer | Aadi Bioscience, Inc. |
| Used for | 1 INDICATIONS AND USAGE FYARRO ® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dosage of FYARRO is 100 mg/m 2 administered as an IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of FYARRO is 100 mg/m 2 administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. 2.2 Dosage Modifications for Adverse Reactions Table 1 lists the r |
| Active ingredient(s) | SIROLIMUS |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f9bb784-53e2-46f9-a65d-1c6c2a230eaf |